Jefferies Reiterates Buy Rating On KND Amid RHB Acquisition

Jefferies is reiterating its Buy rating on shares of Kindred Healthcare Inc. KND. “KND delivered impressive Q1 results, as strong rate growth, improving volume trends and solid cost controls all converged to drive a $0.17 Q1 EPS beat,” Jefferies writes. “In our view, the company's success underscores its compelling long-term outlook, which will likely be enhanced by the incremental scale and scope provided by the pending RehabCare RHB acquisition.” Kindred Healthcare closed Monday at $24.23.